Scanner DailyTickers — Thursday, May 7, 2026

Dell Technologies gapped to a new 52-week high on a massive +10.4% session. The AI server backlog is accelerating — Dell is the #2 AI server OEM behind HPE, benefiting from the same hyperscaler capex cycle that drove AMD’s +17.8% beat today. Enterprise PC refresh cycle adds a second revenue driver. Forward PE 16.2x is reasonable for a company delivering 15%+ revenue growth. The $155B market cap and 9.1M volume (vs 3.7M avg) confirm institutional participation. Weak DXY boosts 50%+ international revenue. The BUY signal from May 5 is already validating at $216 → $239.

Corning is the monopoly supplier of optical fiber for data center interconnects — the physical backbone of AI infrastructure. The stock surged +12% to a new 52-week high on extraordinary volume: 31M shares traded vs 925K average (33x normal!). This level of volume conviction from institutions is rare and signals a structural re-rating. Every hyperscaler expansion (MSFT Azure, GOOGL Cloud, AWS, META) requires massive fiber optic buildout, and Corning controls 35%+ of the global market. The AI data center interconnect market is projected to grow 25%+ annually through 2028.

DaVita gapped +23.5% to a new 52-week high on an earnings blowout. As the largest kidney dialysis provider in the US, DVA benefits from an aging population, pricing power from Medicare reimbursement increases, and operational efficiency gains. Forward PE 11.6x is deep value for a healthcare compounder. The stock was consolidating between $148-157 for months before exploding higher — this is a genuine breakout from a multi-month base. Volume of 2.9M confirms the institutional bid.

IFF surged +17.2% to near its 52-week high ($84.45) on an earnings beat. As the global leader in flavors and fragrances (ingredients for food, beverages, personal care), IFF has defensive consumer staples characteristics with specialty chemicals growth. Portfolio optimization and margin improvement are driving earnings inflection. Forward PE 17.5x is reasonable. Volume 4.2M vs historical avg confirms institutional accumulation.

Goldman Sachs is riding a sustained momentum wave, trading at $937 with the ATH at $984 within reach. The M&A advisory revenue cycle is accelerating in RECOVERY regime — IPO pipeline is the strongest since 2021, and dealmaking sentiment is bullish. Forward PE 14.3x is cheap for a bulge-bracket bank generating 17%+ ROE. The BUY signal from March 31 ($827) has already delivered +13.3%. RECOVERY regime favors risk-taking financials like GS over defensive banks.

Sanofi is Europe’s largest pharmaceutical company by market cap ($179B), approaching its 52-week high of $13.24. The Dupixent franchise (atopic dermatitis, asthma) is the growth engine, delivering double-digit revenue increases. Forward PE 9.9x is remarkably undervalued vs US pharma peers (LLY 55x, ABBV 14x). Dividend yield 2.35% provides downside cushion. The BUY signal from March 31 ($10.99) has delivered +12.8%, and the momentum structure above both 50-DMA and 200-DMA is clean. EUR strength (weak DXY) is a tailwind for ADR pricing.

AstraZeneca pulled back from its 52-week high of $212.71 to $184.92, offering a quality pullback entry in the best oncology pipeline in pharma. Enhertu (breast cancer), Tagrisso (lung cancer), and Imfinzi (bladder cancer) are multi-billion dollar franchises. Market cap $287B with forward PE 21.2x is reasonable for a company delivering 15%+ revenue growth. The BUY signal from March 30 ($193.88) saw the stock retreat to 200-DMA support, now bouncing. R/R of 1:1.9 is the best in the scan.

Sea Limited broke above the $90 level on a +6.6% session, reclaiming a key technical resistance. As the leading e-commerce (Shopee) and fintech (SeaMoney) platform in Southeast Asia, SE is a pure play on the region’s digital economy structural growth. Forward PE 18.4x is reasonable for a company delivering 25%+ revenue growth. The BUY signal from April 27 ($85.49) is playing out. Southeast Asian digital economy is projected to reach $600B by 2030. Weak DXY is a direct tailwind for APAC assets.

EEM hit a new 52-week high at $67.59 on massive volume of 35M shares. This is the clearest signal that the RECOVERY is broadening beyond US equities into emerging markets. Weak DXY (98.5) is the primary EM tailwind — every 1% DXY decline historically translates to 0.5-1% EM outperformance. The BUY signal from April 1 ($57.23) has already delivered +17.9%. China reopening, India growth, Korea semiconductor cycle, and Brazil commodity tailwinds are all converging. The ETF diversifies across 1,400+ holdings, reducing single-country risk.

EFA captures the developed international recovery across Europe, Japan, and Australia. The ETF is near its 52-week high ($105.94) after surging +2.71% on broad risk-on flows. BUY signal from April 30 ($101.54) is active. European corporate earnings are accelerating, Japanese governance reforms are unlocking shareholder value (record buybacks), and Australian resource companies benefit from China demand. DXY weakness at 98.5 boosts all non-US assets. Volume of 14.7M confirms institutional participation. RECOVERY regime broadening into international developed markets validates the EFA thesis.